Coming Soon: A Multi-Drug Cocktail for Hepatitis C
Similar to how AIDS is now treated, pharmaceutical and biotech companies are racing to come up with the optimal oral combination of drugs that can safely suppress Hepatitis C.
Continue reading »Hepatitis C Treatments/Therapies
Locteron Triumphs in Phase 2 Hepatitis C Trial
With dosing once every other week, a similar effectiveness as PEG-Intron and fewer side effects, Locteron's Phase 2B trial is successful.
Continue reading »Nitazoxanide and IC41 Take on Interferon and Ribavirin
Intercell's investigational, therapeutic Hepatitis C vaccine, IC41, and Romark's antiviral drug, nitazoxanide, will be studied together to see if their effectiveness at fighting Hepatitis C can top the current standard of treatment - pegylated interferon and ribavirin.
Continue reading »Unique Oral Drug Combo Acknowledged as Potential Hepatitis C Therapy
A small study found that combining two oral drugs (not including interferon or ribavirin) demonstrated potential in treating Hepatitis C without many serious adverse events.
Continue reading »Achillion Kicks Off Dosing Trial for Hepatitis C Drug
As Phase II trials to determine a dosing schedule for ACH-1625 begin, Achillion gets closer to a safe and tolerable medication for suppressing the Hepatitis C virus.
Continue reading »Study Boasts Taribavirin Advantage Over Ribavirin for HCV Treatment
Previously known as viramidine, taribavirin is less able to enter red blood cells than ribavirin. When substituted for ribavirin during Hepatitis C combination therapy, researchers found that appropriate dosing of taribavirin reduced the anemia rate while increasing the treatment's efficacy.
Continue reading »Development of Two HCV Experimental Drugs Halted
Liver-related side effects prompted the FDA to stop trials with two Idenix drugs in development for treating Hepatitis C.
Continue reading »Previous HCV Non-Responders Win in Phase III Telaprevir Study
An international, Phase III study reports that 65 percent of previous non-responders with the most common Hepatitis C genotype achieved a sustained viral response with a telaprevir-based regimen. These results are dramatic, compared to the mere 17 percent of sustained viral response by those who received pegylated-interferon and ribavirin alone.
Continue reading »New Stem Cell Technology Could Benefit Hepatitis C
Sep 9, 2010
2 Comments
Researchers from England have been able to transform skin cells into liver cells - a feat that could have major implications for those fighting Hepatitis C.
Continue reading »TV Show Delivers Hope for Hepatitis C
A recent television news piece helped boost awareness of Hepatitis C - but it also may have created false hope by alluding to the speedy arrival of a Hep C cure.
Continue reading »
